Two Indiana University studies conducted among nationally representative samples of adult American men and women show that vibrator use during sexual interactions is common, with use being reported by approximately 53 percent of women and 45 percent of men ages 18 to 60. Not only is vibrator use common, but the two studies also show that vibrator use is associated with more positive sexual function and being more proactive in caring for one’s sexual health.
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
A long-term study by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that the three most common treatments for localized prostate cancer had significant impacts on patients’ quality of life, a finding that could help guide doctors and patients in making treatment decisions.
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
UroToday.com - Together with Drs. Heruti, Bechor, Justo and Galor, we studied 815 Israeli male adults of whom 305 had complete data and were included in the statistical analysis. In the analyzed population, 2.1% of people without erectile dysfunction (ED) had advanced periodontal disease (defined as recession of periodontal bone of 6 mm or more) in comparison to 9.8% of the mild ED and 15.8% of the moderate/severe ED populations, respectively.
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
UroToday.com - This updated review of tadalafil (Cialis), one of the three available phosphodiesterase type 5 (PDE5) inhibitors that revolutionized the treatment of erectile dysfunction (ED), analyzes its latest clinical studies. Tadalafil’s most unique and identifying characteristic is its long half-life of 17.5 hours, compared with 4 hours for sildenafil (Viagra) and vardenafil (Levitra).
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
Premature ejaculation can be embarrassing, but a new study suggests that it might be a genetic disorder. Researchers from Turku, Finland, interviewed more than three thousand men - all pairs of male twins and their older or younger brothers - about the first time they had sex. Many participants in the study reported that they had suffered from erectile dysfunction and premature ejaculation at their first sexual encounter.
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED).
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
Eli Lilly and Company (NYSE: LLY) announced results from a double-blind, placebo-controlled study which showed that tadalafil 5 mg dose taken once daily was generally well-tolerated, improved erectile function for men with erectile dysfunction (ED) and reported improvement in the sexual quality of life scores for men and their female partners.
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) announced preliminary results for its sexual dysfunction drug candidate, Zoraxel™, from a Phase IIa clinical study for the treatment of erectile dysfunction (ED).
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
Sciele Pharma, Inc. a Shiongi Company, and Plethora Solutions Holdings PLC (”Plethora” - AME:PLE) today presented highly encouraging results from a European Phase III randomized, double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation (PE). In this study, men treated with PSD502 five minutes before intercourse were able to delay ejaculation up to six times longer than those who used a placebo.
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today
Several new studies presented at the American Urological Association’s (AUA) 104th Annual Scientific Meeting suggest that the use of statins–commonly prescribed to lower cholesterol–may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS). Several key research studies highlighting these benefits will be presented during a special panel for the media on Monday, April 27 from 9 to 10:30 a.m.
Original post by Erectile Dysfunction / Premature Ejaculation News From Medical News Today